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Abstract 
The use of molecular signatures to add value to standard clinical and pathological 
parameters has impacted clinical practice in many cancer types, but perhaps most 
notably in the breast cancer field. This is, in part, due to the considerable complexity 
of the disease at the clinical, morphological and molecular levels. The adoption of 
molecular profiling of DNA, RNA and protein continues to reveal important 
differences in the intrinsic biology between molecular subtypes and has begun to 
impact the way patients are managed. Several bioinformatic tools have been 
developed using DNA or RNA-based signatures to stratify the disease into 
biologically and/or clinically meaningful subgroups. Here, we review the approaches 
that have been used to develop gene expression signatures into currently available 
diagnostic assays (e.g. OncotypeDX® and Mammaprint®), plus we describe the latest 
work on genome sequencing, the methodologies used in the discovery process of 
mutational signatures, and the potential of these signatures to impact the clinic. 
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Introduction 
Breast cancer is an extremely diverse and complex disease, and is one of the leading 
causes of death amongst women. There is marked tumour heterogeneity between 
patients, with specific breast cancer subtypes associated with differing prognoses. 
Differentiating breast tumour types is a key component of the clinical management 
process to ensure patients are given the most appropriate type of therapy. In this 
review we briefly illustrate the best practices in tumour classification from a 
pathology context, including currently utilised predictive and prognostic biomarkers. 
We will then highlight the advances made in the molecular arena, which have shed 
light onto the differences in intrinsic biology between subtypes of the disease and how 
these have been developed into molecular signatures with clinical utility.  
 
Pathological Classification of Disease 
As part of the diagnostic process, a pathologist examines a tissue biopsy or resection 
specimen. A diagnosis will be made based on key parameters, which include 
histological type, tumour grade, and tumour stage using criteria outlined by the World 
Health Organisation (WHO) [1]. There are at least 20 different histological subtypes 
of breast cancer, which display differences in morphology and growth pattern. The 
most common is Invasive Carcinoma of No Special Type (IC-NST; previously called 
Invasive Ductal Carcinoma (IDC) accounting for 80% of all cases [1]). The remaining 
are classified as ‘special’ histological types in that they exhibit unique patterns of 
growth. Invasive Lobular Carcinoma (ILC) is the most common special type, 
accounting for between 5-15% of cases, with others including medullary, metaplastic, 
tubular and mucinous subtypes which all have distinctive growth patterns and variable 
prognoses.   
Several diagnostic systems give insight into the behaviour of a tumour, including 
tumour grade and stage (Figure 1). Histological grade describes how abnormal the 
tumour appears relative to normal tissue, as a measure of tumour cell differentiation. 
Grading of breast cancer is performed using the Nottingham grading system [2, 3]. 
This is a three-tiered scoring system, assessing the number of visible mitoses, the 
presence of tumour cells creating tubule structures and evidence of nuclear 
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pleomorphism. The number of mitoses acts as a surrogate for growth rate, while 
tubule formation is a measure of whether the tumour tissue resembles normal-like 
ductal structures. Pleomorphism is a measure of the size, shape and variability of 
tumour nuclei. The prognostic value of the grading system in predicting behaviour 
and patient outcome has long been established [4, 5]. A histological grade 1, well-
differentiated tumour is associated with a significantly better prognosis compared to a 
grade 3, poorly differentiated tumour. 
Tumour Stage is a measure of how far the tumour has spread, and so is also a highly 
prognostic tool. The American Joint Committee on Cancer (AJCC) TNM staging 
system is used for most organ systems, including breast. T is a measure of the tumour 
size (<2cm, between 2-5cm and >5 cm) and whether the tumour has invaded the chest 
wall; N refers to the number of lymph nodes that show evidence of cancer (0, 1-3, 4-
9, >10) and the position of the node in the nodal system; and M is a measure of 
distant metastasis, i.e. if there is a sign of cancer spread beyond the site of the primary 
tumour.  
 
Clinical biomarkers in breast cancer 
Biomarkers play important roles in diagnosis and prediction of prognosis, and may 
also represent therapeutic targets. Key breast cancer biomarkers include Oestrogen 
Receptor (ER), Progesterone Receptor (PR) and Human Epidermal Growth factor 
Receptor 2 (HER2/ERBB2); these markers have been reviewed extensively and their 
expression correlates with differences in tumour behaviour and patient outcome and 
the potential response to targeted endocrine therapy or HER2 therapy [6]. The protein 
expression levels of ER, PR and HER2 are assessed using immunohistochemistry and, 
in addition, the ERBB2 gene copy number is also quantified using in situ 
hybridization [7]. If a breast cancer is positive for either ER or PR the breast cancer is 
termed as Hormone Receptor positive (HR+) and these patients will likely receive 
endocrine therapy, while patients with HER2+ breast cancers will receive trastuzumab 
or other HER2 targeted therapies.  According to the Surveillance, Epidemiology, and 
End Results (SEER) survey that covers 28% of the North American population, 
72.7% of breast cancer patients had HR+/HER2- disease, 14.9% had HER2+ disease 
(of which, 10.3% were HR+/HER2+ and 4.6% were HR-/HER2+) and 12.2% had 
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triple-negative disease [8]. As the name suggests, triple-negative breast cancer 
(TNBC) encompasses all tumours that are negative for ER, PR and HER2. The 
majority of TNBC are high-grade and aggressive tumours associated with a poorer 
outcome than other breast cancer subtypes, despite a good response to chemotherapy 
[9].   
Ki67 is a proliferative marker used to predict tumour growth rate, which has been 
shown to be a prognostic biomarker with predictive ability in the adjuvant context 
[10-14]. Ki-67 staining has not yet been fully translated to the clinical setting owing 
to difficulties in standardising technical aspects of the procedure, including 
appropriate scoring methods and thresholds [15, 16].  
A combination of the 4 IHC based biomarkers (ER, PR, HER2 and Ki67) exists as a 
protein-based ‘signature’. This panel was termed IHC4 and the algorithm has been 
validated as a predictor of risk of distant recurrence in breast cancer [17, 18]. 
Although the current well-established clinical variables mentioned above show 
associations with prognosis and outcome, there are increasing concerns that these 
variables are limited in their ability to capture the diversity of breast cancer and tailor 
the therapy to individual patients.  
Various methods have been developed to help improve the management of breast 
cancer patients based on the combination of this clinical, pathological and biomarker 
data that is collected at diagnosis. Various tools have been developed (e.g. Adjuvant! 
Online, Predict, the Nottingham Prognostic Index (NPI)) to help inform clinicians 
about their patient's potential prognosis and whether they are likely to benefit from 
adjuvant therapy following breast cancer surgery. These mathematical algorithms 
incorporate various clinical and pathological variables described above (patient age, 
tumour size, grade and lymph node status) together with tumour expression of these 
molecular biomarkers (ER, HER2 and Ki67) to predict survival with or without 
adjuvant therapy. The NPI is a highly prognostic tool based on combining 
pathological parameters of tumour size, tumour grade and the number of axillary 
lymph nodes that are involved with tumour. The NPI Plus was recently developed to 
incorporate a panel of 10 immunohistochemical biomarkers of demonstrated 
prognostic significance [19]. This modification identifies prognostic subgroups within 
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the well-described molecular subtypes of disease (ER+, HER2+ or triple negative) 
and so may provide additional benefit to managing the individual patient. 
 
Developing mRNA based gene classifiers 
Gene expression profiling of breast cancer has illustrated that the disease exhibits 
significant molecular heterogeneity, even among tumours with the same 
morphological features. This has led to the development of classification tools to 
stratify tumours into diverse molecular subtypes that have clinical relevance. To 
briefly illustrate the power of this approach, the early analysis of just 84 breast 
tumours by hierarchical clustering using genes whose expression levels differed from 
the median revealed several molecular subtypes of disease, including the Luminal A, 
Luminal B, Her2-enriched and Basal-like, as well as a normal-like group [20].  Each 
of these subtypes is clinically important as they exhibit differences in incidence, 
prognosis and response to therapies [21]. For example ER+ breast tumours are a 
heterogeneous group, which can be stratified, in simple terms, into Luminal A and B 
subtypes. The luminal A subtype has the best prognosis, whereas the Luminal B 
subtype collectively describes an aggressive group of tumours with a higher 
proliferative index indicated by Ki67 or Aurora A kinase (AURKA) staining. The 
amplification and overexpression of HER2 contributes to this aggressive behaviour in 
some Luminal B tumours [22] along with the activation of a plethora of other 
oncogenes found in regions of recurrent gene amplification (e.g. at 8p11-12 and 
11q13) [23]. This work has therefore had a significant impact on the way breast 
cancer is described, researched and managed clinically. The classification of these 
‘intrinsic’ subtypes has evolved since this first description, and they can now be 
defined by a 50 gene quantitative measurement known as the PAM50 subtype 
classifier [21], which is commercially packaged as a diagnostic classification tool 
called Prosigna® [24], for use in clinical practice (see below).  
Gene signatures are sets of genes, or meta-genes, that together have predictive power 
to differentiate tumours based on broader biology; and so in this sense they are a form 
of biomarker. The process of identifying gene signatures can be summarised into a 
few key steps, illustrated in Figure 2, and with specific examples given below. Each 
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step requires a unique set of skills within a multidisciplinary team.  The first step is 
signature discovery and involves acquiring a retrospective tumour cohort reflecting 
the clinical question in mind, together with detailed clinical history data on the 
patients. The tumour samples within the cohort would then be subject to molecular 
profiling by gene expression arrays, historically, or by whole transcriptome 
sequencing (RNAseq). A class comparison or regression analysis would be performed 
to identify an initial set of genes that best discriminate between a phenotype or an end 
point of interest, such as survival. Various filtering steps such as cross-validation 
would then be applied to arrive at a minimal set of genes predictive of the end-point. 
A scoring algorithm, which may include clinical features such as the tumour size or 
the number of lymph nodes involved, would be developed to assign thresholds or 
scores to classify the tumours into groups. The analysis of a validation cohort, 
together with permutation-based testing would be used to evaluate the robustness of 
the gene signature. Such statistical tools are user-friendly and allow the comparison of 
the performance of the signature against random gene sets and known gene 
signatures. Individual biomarkers from the signature might be studied in a candidate 
gene approach, for functional implications in the disease or as a surrogate biomarker 
in clinical samples. For clinical implementation, a prospective evaluation of the 
biomarker or gene signature would be required to determine the robustness of the 
signature in identifying risk groups with distinct clinical outcomes. 
A single sample predictor (SSP) is a strategy that has been employed in order to best 
classify an individual tumour into one of several predefined molecular subtypes, such 
as those mentioned above. The idea being that an individual tumour can be classified 
based on how similar its gene expression profile associates with the molecular based 
centroids of these subtypes, and hence the approach should not need the simultaneous 
profiling of a group of cases for classification. An SSP would therefore have clinical 
utility, similar to other simple biomarkers currently used in diagnostic practice, to 
classify tumours into clinically meaningful groups (e.g. with distinct response to 
therapy, risk of relapse and/or outcome). In practice, SSPs have some limitations, 
including low concordance rates on sample assignment across several studies [25] 
[26]. In particular a lack of concordance was observed amongst the assignment of 
tumours into Luminal A, Luminal B and HER2 subtypes. These findings were further 
supported by those of a meta-analysis from a diverse set of different microarrays 
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which showed a limited concordance of SSPs in 22 uniformly pre-processed datasets 
in 4000 hybridizations [27]. Based on these findings, the reliability of single sample 
predictors has been brought into question, which could be based on the bioinformatics 
algorithms used for classifications [28] (Figure 3) and/or be due to the biological 
nature of disease, which in the case of luminal/HER2 tumours is a spectrum of disease 
rather than being discrete entities that are easily stratified.  
An alternative approach is the development of subtype classification models (SCM), 
which have an advantage over SSPs in their versatility. An SCM can be applied to 
different microarray platforms and a variety of normalisation methods [29-32]. To 
illustrate this concept, a subtype classification model was developed using a mixture 
of three Gaussian distributions representing three important breast cancer phenotypes 
(ER, HER2 amplification signalling and cell proliferation) in a two-dimensional space 
[29, 32] (Figure 3). The model consisted of co-expression gene modules representing 
these phenotypes, each consisting of genes associated with the key biological process. 
These ER, HER2 and proliferation co-expression gene modules were derived from a 
meta-analysis of 2,833 breast tumours, using a multiple regression approach with a 
Gaussian error model. For example, the ER gene module consisted of a set of 288 
genes with correlated expression to ESR1; similarly there were 20 genes in the HER2 
module and there were 355 genes in the proliferation module [29]. These modules 
were refined to a single three-gene subtype classification module using the 3 original 
prototype genes (ESR1, ERBB2 and AURKA) in 5715 tumours [32]. In a comparative 
analysis in this large dataset, three different SCM classifiers, including the three gene 
SCM, were compared to three SSPs for molecular subtypes classification; the SCMs 
were shown to be more robust than SSPs at subtype classification and provided 
similar prognostic value [32]. Strong correlations of the raw prediction scores were 
observed in tumours profiled with different technologies (i.e. Affymetrix microarray 
and Illumina RNA-seq) [33], confirming that the subtype classifiers (SSPs and SCMs) 
can be transferred from microarray to RNA-seq technologies. 
An analyst wishing to define a prognostic gene signature must also be aware of the 
fact that genes can be associated with outcome purely by chance. Enlightening 
research by Venet et al. revealed that randomly selected gene sets may be associated 
with breast cancer outcome, to some degree [34]. It is necessary, therefore, for robust 
checks to be implemented to ensure that a gene signature is unique in its ability to 
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prognosticate compared to other randomly chosen genes that are prognostic by 
chance. The package Sigcheck has been developed to deal with this particular issue 
[35] (Table 2) and compares the performance of an identified gene signature against 
the performance of known and random signatures through permutation testing. 
Commercially available mRNA-based diagnostic tests 
There are several commercially available mRNA-based diagnostic tests for 
prognostication and prediction in breast cancer. These gene expression panel assays 
are risk predictors and examples include: MapQuantDX™ (Genomic Grade Index, 
GGI) [36], ProSigna® [24] [37], Mammaprint® [38], OncotypeDX® [39] and 
EndoPredict® [40] (Table 1). Each predictor was derived in a different manner and 
using a unique algorithm, but collectively they classify the risk of recurrence of breast 
cancer, and hence provide insight into whether a patient might require adjuvant 
chemotherapy or not. From a bioinformatic point of view, the original 
implementations of the mRNA signatures are available in the R programming 
environment through the package genefu [41]. This is therefore a particularly useful 
package, the ‘swiss army knife’ of gene expression signatures and can be added to 
any bioinformatics analysis pipeline (Table 1) to enable in silico comparison between 
these established signatures and novel metagene sets using publically available gene 
expression data.  
The Genomic Grade Index (GGI; MapQuantDX™) is an RT-PCR-based assay that 
can be applied to formalin fixed, paraffin embedded (FFPE) tissues and is performed 
by a centralised laboratory to predict the risk of distant recurrence in ER-positive 
breast tumours. The GGI was first developed through testing the hypothesis that gene 
expression profiling could add value to conventional histological grading. Grade 1 
and 3 tumours exhibit low and high risks of recurrence, respectively, and hence 
patients can be managed with some confidence. However, patients diagnosed with 
grade 2 disease are more challenging to manage and so the intent with the GGI was 
specifically in stratifying grade 2 tumours into good (grade 1-like; low risk of 
recurrence) and poor (grade 3-like; high risk of recurrence) prognostic groups [36]. 
This tool was derived from a total set of 64 ER positive tumour tissue samples and a 
comparison was performed between grade 1 and grade 3 tumours using a differential 
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gene expression analysis. The GGI score was determined through the difference of the 
log-transformed gene expression values of grade 3 and grade 1 associated genes. The 
tumour cohort was scaled and normalised further using offset parameters finally 
revealing a total of 97 genes [36], which were validated in an independent set of 125 
patients as being able to stratify grade 2 tumours into grade 1-like and grade 3-like. A 
cut-off point of the GGI score was determined rather than utilising GGI as a 
continuous score, whereby high risk was defined as (GGI ≥0) and the low-risk group 
was defined as (GGI<0). The GGI was investigated alongside other signatures in a 
large cohort of 2833 patients, highlighting the importance of proliferation-associated 
genes in breast cancer prognostication [29]. Subsequent evaluation in various clinical 
cohorts demonstrated the utility of this signature, relative to other measures of a 
tumours proliferative capacity (Ki67 staining, histological grade, mitotic activity) for 
predicting disease free survival [42-47]. 
ProSigna® is the commercial iteration of the PAM50 subtyping tool, and generates a 
risk of recurrence score primarily to predict chemotherapy benefit [21, 24, 37, 48]. 
ProSigna® is applied using the nanoString nCounter Analysis System, to obtain 
digitally quantified gene expression levels, even for archival (FFPE) tumour material. 
A prognostic risk model was developed by applying the PAM50 subtype predictor in 
combination with various clinical-pathological parameters (tumour size and grade), to 
a series of published breast cancer datasets, including the 141 cases of node negative, 
untreated disease from the NKI cohort that was previously used to develop 
Mammaprint [21, 38]. The risk of recurrence (ROR) score (combination of PAM50 
plus clinical parameters) outperformed the use of clinical parameters alone or 
molecular subtype classification alone for predicting outcome [21]. The PAM50 assay 
was validated in the ABCSG-8 trial as a prognostic tool for distant recurrence-free 
survival (DRFS) [49]. This trial consisted of a set of 1478 patients with 
postmenopausal, early stage ER positive breast cancer who received endocrine 
therapy [49]. All examples of the 4 intrinsic subtypes were present in this cohort, as 
were all ProSigna risk groups (i.e. low, intermediate and high). Patients had a 
probability of 10 years DFRS of 96.7% when classified as low risk, 91.3% for 
intermediate risk and 79.9% for high risk [49], showing the clinical value of this gene 
signature. Importantly, ProSigna is suitable for use in core needle biopsies in the 
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neoadjuvant chemotherapy setting [48] and has also revealed an accurate estimation 
of the risk of distant recurrence in estrogen receptor-positive (ER+), node-negative 
patients treated with five years of adjuvant tamoxifen, [24].  
MammaPrint® is a microarray-based 70-gene assay that is performed by a centralised 
service on fresh frozen tumour material. The set of 70 genes were originally derived 
using 98 patients, 34 of which developed metastatic disease and 44 were metastasis 
free after 5 years follow up [38]. The neat hypothesis underpinning its development 
was that the expression of a unique set of genes could distinguish between a good and 
poor prognosis. The transcriptome was profiled and a filtered set of approximately 
5000 genes were obtained based on their ≥2.5 fold differential expression between the 
‘metastasis’ and ‘no metastasis’ groups at a statistical significance of p<0.01 [38]. A 
supervised classification model was then generated after extensive feature selection 
[38], as outlined. The first step involved correlating gene expression of each gene 
with each prognostic category (metastasis vs. non-metastasis). Significant random 
gene correlations were accounted for using 10,000 Monte Carlo simulations, 
identifying 231 genes with a correlation coefficient >0.3 and less than -0.3. “Leave 
one out” cross validation was applied and the left out sample was correlated with a 
good or poor prognosis template. This template is the average gene expression value 
in each prognostic group. Iteratively, five markers would be added to the classifier 
from the top of the list of 231 candidates (based on correlation coefficient) until 231 
markers were used. The optimal performance of the classifier was reached using 70 
genes and thus defining the MammaPrint set to predict poor prognosis. The 
MammaPrint recurrence score is based on the correlation coefficient of each sample 
with the good prognosis template. The TRANSBIG consortium and member countries 
of the Breast International Group (BIG) have validated the power of MammaPrint in 
distinguishing between low-risk patients and patients with a high risk of distant 
recurrence and survival [50]. The Microarray In Node negative and 1 to 3 positive 
lymph node Disease may Avoid ChemoTherapy (MINDACT) trial [51] was 
performed to provide evidence from a large-scale, prospective, randomised controlled 
phase III international clinical trial for the value of integrating MammaPrint into 
clinical practice. Interestingly, the study reported that in 6693 patients, 23.2% were 
classified as high clinical risk and low genomic risk. Based on the clinical risk factors 
these patients would ordinarily have been given chemotherapy, yet, since patients 
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were classified as low-risk based on the gene signature, they were not given 
chemotherapy. The rate of 5-year survival was 94.7% in this clinically and genomic 
discordant risk group [51], suggesting that using the genomic risk predictor to identify 
low-risk patients might be clinically useful in recognising a target population that will 
have a good prognosis without chemotherapy, despite having contrary clinical 
indicators of high-risk disease.  
OncotypeDX® is a 21-gene panel that was derived using a unique approach; a high 
throughput Real-time PCR (RT-PCR) approach was used to quantify the expression 
of a targeted panel of 250 candidate genes identified through a combination of 
literature analysis, genomic-focused databases, pathway analysis and from the 
analysis of publically available microarray gene expression profiling data [39]. The 
expression level of these genes was examined in three independent cohorts [52-54] of 
447 patients, spanning different tumour and treatment types. This approach was used 
to refine the 250 genes down to a powerful prognostic metagene, rationalised by 
considering that genes robustly associated with recurrence would need to be present 
in all three cohorts. Nine genes displayed highly correlated expression with 
recurrence across all cohorts (P<0.05), five genes displayed correlated expression 
with outcome in all cohorts (P<0.01), and the expression of an additional nine genes 
correlated with outcome in two studies (P<0.05). A final set of 16 genes was selected 
based on the technical performance of the genes in the RT-PCR assay. This 21-gene 
assay (16 cancer genes plus 5 reference genes) constitutes the OncotypeDX assay, and 
encompasses genes involved in oestrogen signalling (ESR1, PGR, BCL2, SCUBE2), 
HER2 (GRB7 and ERBB2) and proliferation (MKI67, AURKA, BIRC5, CCNB1 and 
MYBL2). OncotypeDX was initially tested in 668 patients from the tamoxifen-treated 
NSABP B14 trial; where the recurrence score was significantly associated with both 
relapse free- and overall-survival and performed better than most clinical-pathological 
parameters at predicting risk of distant recurrence. The clinical utility of OncotypeDX 
has been evaluated in numerous retrospective clinical trial cohorts [43] and was 
recently evaluated in the TAILORx (Trial Assigning IndividuaLised Options for 
tReatment) [55] and RxPONDER (Rx for POsitive NoDe, Endocrine Responsive 
breast cancer) [56] phase III prospective clinical trials. Both trials involved patients 
with ER+ HER2- breast cancer and either lymph node negative disease or lymph node 
positive disease, respectively and investigated whether patients with low-intermediate 
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risk of recurrence scores by OncotypeDX could be treated with endocrine therapy 
alone or also required chemotherapy. While data from RxPONDER trail matures, the 
results from TAILORx demonstrated that patients with a recurrence score between 0 
and 10 given endocrine therapy alone had a 5-year disease free survival rate of 93.8% 
and overall survival at 5 years of 98% [57]. Similar to MammaPrint, OncotypeDX 
therefore identifies a low-risk group of patients who have favourable outcomes, with 
little need for chemotherapy. 
EndoPredict is another RNA-based multigene panel that was developed from the 
analysis of ER+ HER2- patients treated with adjuvant endocrine therapy [40]. The 
development of this signature employed a multistep-step approach beginning with the 
analysis of a training cohort of 253 primary tumours by Affymetrix gene expression 
arrays. The gene list was selected by prioritizing probes with a dynamic range 
(defined as the ratio between the 90
th
 and 10
th
 percentile) of expression of ≥2, plus 
those with published evidence of being prognostic in breast cancer. Cox regression 
analyses were conducted using the time to distant recurrence as the endpoint. A total 
of 104 candidate prognostic genes, based on their ranked p-value in the model and 
various analytical parameters, were tested by RT-PCR, using FFPE tumour tissue. A 
refined set of 63 genes had high performing primer-probe pairs, and a linear 
relationship between RT-PCR and logged (base 2) Affymetrix probe hybridisation 
values. The algorithm was trained using distance recurrence as the end point and a 
leave one out cross validation approach, which identified 8 genes that constitute the 
EndoPredict signature: three proliferation associated genes and five genes associated 
with ER-signalling/differentiation: BIRC5, UBE2C, DHCR7, RBBP8, IL6ST, AZGP1, 
MGP, and STC2 (plus an additional three reference genes) [40]. From a 
bioinformatics perspective, the algorithm involved a committee predictor consisting 
of a fixed number of members, where each member is a linear combination of a few 
input variables. A committee predictor was used, as these low dimensional linear 
combinations tend to yield more powerful and robust prediction algorithms. The 
signature was evaluated in two large randomised phase III trials involving patients 
with ER+ HER2- disease treated with tamoxifen. Endopredict (EP) generated a risk 
score that was shown to be an independent predictor of subsequent risk of distant 
recurrence at 5 or 10 years. The power of this gene set was further improved with the 
integration of clinical parameters (tumour size and nodal status) into the diagnostic 
  
 13 
algorithm (EPClin) [40]. The prognostic value of EP and EPClin were independently 
verified using the TransATAC trial (the Translational substudy of the Arimidex, 
Tamoxifen, Alone or in Combination trial (ATAC)), where they outperformed 
OncotypeDX in predicting late distant recurrence after endocrine therapy, though 
some of this benefit came from the integration of clinical parameters into the gene 
signature [58]. 
This latter point is an important factor in the evaluation of these gene expression-
based molecular signatures in the clinic. Although they were not all developed with 
the same intention, each of the signatures discussed describe a commonality in 
predicting risk of recurrence in the setting of ER positive disease. They each appear 
useful tools for identifying a very good (low risk) prognostic group that could be 
spared the toxicity of chemotherapy. Many of these patients would have been 
classified low risk based on clinical and pathological features alone. However, one 
particular benefit of the molecular signatures over standard clinical-pathological 
parameters appears to be in identifying molecular low risk patients that were 
classified as high risk based on clinical parameters. These patients will also benefit 
from being spared the toxicity of chemotherapy, without affecting their prognosis.  
From a clinical point of view these are important advances, however given the 
overlap in clinical utility across the spectrum of signatures, it begs the question of 
which gene signature is the most appropriate or most robust or gives most benefit?  
Studies using the TransATAC trial, and others, have made useful progress in 
retrospectively comparing signatures (including the IHC4, 21-gene Oncotype DX, 
PAM50/Prosigna, EP/EPclin) within the controlled environment of a clinical trial [43, 
58, 59]. The OPTIMA trial (The Optimal Personalised Treatment of early breast 
cancer using Multiparameter Analysis) was designed to prospectively compare 
multiple molecular signatures to identify patients who would most benefit from 
chemotherapy [60]. These comparative studies illustrate that the molecular tests 
provide broadly comparative prognostic information and hence similar risk 
stratification at the population level, and that the integration of clinical and 
pathological parameters into the molecular signature provides increased power in 
prognostication. However, importantly, at the patient level there remains discrepancy 
in classifying individual patients into different risk categories depending on the test 
used, which is presumably related to the different methods and clinical scenarios used 
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to develop the signatures in the first place, and the different panels of genes being 
analysed.  
 
DNA Signatures in Breast Cancer   
All cancers are characterised by the acquisition of somatic mutations to the tumour 
genome, including base substitutions, insertions and deletions, copy-number changes 
and structural rearrangements. The diversity of this “genomic landscape” among 
individual tumours is considerable. Some alterations directly affect key cancer genes 
(driver events) that confer selective growth advantage upon tumour cells, and may be 
useful therapeutic targets (e.g. HER2 amplification). Other mutations (passenger 
events) accumulate over the lifetime of the cell lineage and although individually and 
collectively they may confer little selective advantage to the tumour cell, their 
frequency distribution can serve as a tell-tale imprint of the underlying mutational 
processes that contributed to tumour growth [61, 62]. It is therefore quite rational to 
consider DNA mutation profiles as a diagnostic tool or signature to identify clinically 
useful subgroups of disease based on aetiology, behaviour or outcome.  
Genome-wide DNA copy number alterations are derived from array-based 
Comparative Genomic Hybridization (aCGH) or single nucleotide polymorphism 
(SNP) arrays. Some copy number alterations of key genomic regions are highly 
prognostic [63], whilst others correlate closely with defects in specific DNA repair 
pathways, such as deficiency in homologous recombination (HR) DNA repair due to 
germline/somatic loss of BRCA1 or BRCA2 [64-71] see below for clinical utility of 
these types of signatures).  
A range of copy number-based classifiers have been determined for breast cancer 
[72], including using variants of random forest [73], logistic regression, logistic group 
lasso[74], fused support vector machine (SVM) [75] and supervised and unsupervised 
feature clustering (FC) using silhouette methods for estimating clusters [76]. Both 
unsupervised and supervised FC performed the best at classifying aCGH data from 
tumour samples, as a result of their ability to remove unwanted correlation bias [72]. 
Compared to other methods tested this approach allowed more accurate features to be 
selected and as a result, greater accuracy could be achieved [72]. This highlights the 
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importance of trialling different models and having key metrics in place to evaluate 
the model. 
Several types of massively parallel sequencing strategies are used to identify 
nucleotide level mutations in the cancer genome. Targeted gene panel sequencing and 
whole exome sequencing (WES) have been most widely applied to characterise the 
mutations in the coding portion of the genome. While whole-genome sequencing 
(WGS) gives comprehensive, unbiased access to the complete repertoire of somatic 
alterations in the genome, including driver events, but also those that are considered 
passenger events. As mentioned above, the pattern and distribution of these passenger 
mutations (base substitutions) can be used to classify mutational signatures, which 
relate to the underlying aetiology of the tumour. There are now 30 mutational 
signatures reported by COSMIC [77]. Whilst many remain of unknown cause, several 
known carcinogenic or defective cellular processes produce characteristic mutation 
signatures. For example, those of lung (C:G > A:T transversions) and skin cancer 
(C:G > T:A and CC:GG > TT:AA transversions) are caused by exposure to 
exogenous mutagens in tobacco, and by ultraviolet light, respectively. Other processes 
that lead to the accumulation of characteristic sets of somatic mutations include 
enzyme modification (e.g. enhanced activation of the DNA cytidine deaminase 
APOBEC3B [43, 78]), infidelity of the DNA replication machinery, or failure of 
DNA repair pathways (e.g. mismatch repair or base excision repair). Mutation 
signatures associated with the inactivation of BRCA1 or BRCA2 are most common in 
breast cancer (and ovarian and pancreatic cancers) and indicate tumours with a 
deficiency in HR- double-strand break repair (HR-DSB) [61, 79, 80].  
In addition to the substitution signatures, patterns of structural rearrangements can 
give insight into tumour aetiology. The largest study of breast cancer whole genomes 
(560 genomes, [79]) defined six re-arrangement signatures based on the type 
(deletions, tandem duplications, inversions and translocations), and size (1 kilobase to 
>1 Mb) of re-arrangement, and the extent of the alteration throughout the genome 
(clustered or dispersed) (Figure 4). Interestingly, three of the signatures were 
associated with BRCA1/2 deficiency, suggesting defective HR DNA repair leads to 
very prominent patterns of DNA mutations, both at the nucleotide and genome 
structural levels.  
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Computational methods for classifying mutation signatures 
Deciphering the signatures of mutational processes in cancer genomes is a blind 
source separation problem [81]. This problem involves unravelling hidden signals in a 
mixture of various signals, without knowing the mixing that was performed. The 
intrinsic non-negative nature of the blind source separation problem requires an 
algorithm that assumes non-negativity of the original source of the signal [81]. The 
primary algorithms for identifying mutational signatures are non-negative matrix 
factorization (NMF) and variants, for instance BayesNMF. There is a two pronged 
approached to NMF; the first approach is to determine the signatures that best account 
for mutational observations. This approach is achieved through mathematical 
optimization implemented to identify factors at a fixed rank of the actual number of 
signatures and a chosen norm.  The second approach is to determine the actual 
number of signatures and this is achieved by further factorising the same data and 
applying a ranking system for different numbers of signatures and the appropriate 
rank is determined by identifying the clustering properties of the factors obtained 
from the original algorithm [82]. The NMF signature discovery approach is now 
available in the R package somaticsignatures [83], which includes visualisation tools 
(Table 2). The Bayesian non-negative matrix (BayesNMF) variant is available here 
(http://archive.broadinstitute.org/cancer/cga/msp). BayesNMF offers analytical utility, 
as you do not have to initially define the number of signatures. An optimal number of 
signatures is determined directly from the data, striking the balance between data 
fidelity and the model complexity [84-86]. Simple model-based approaches of 
signature identification and visualisation are also available (probabilistic mutation 
signature - pmsignature), and differ from the usual NMF approach [87] (Table 2). 
Mutational patterns are often derived from the standard 6 possible substitution 
patterns (C>A, C>G, C>T, T>A, T>C, T>G), however DNA sequence context of the 
substitutions is not taken into account. pmsignature includes the 5’ and 3’ flanking 
bases of the mutated base. This results in 96 patterns, and with strand information 
(plus or minus) further extends the number of possible patterns to 192. This approach 
reduces the number of parameters per signature by dividing each mutational pattern 
into features (i.e. substitution type, 3’ base, 5’ base) [87]. Each mutational signature is 
characterized by the probability distribution for each feature. The decomposition is 
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then analysed using a probabilistic model, which assumes each feature is independent 
and significantly reduces the number of parameters to 18 per signature, unlike the 
3071 parameters per signature employed by other methods [87].  
Both somaticsignature and pmsignature have their advantages and disadvantages 
(Table 2) in yielding mutational signatures that provide further insight into the 
mechanistic underpinnings of these mutational processes. However, the use of these 
tools is not yet widespread due to the cost and challenges associated with processing 
whole genome sequencing data. There is certainly precedence for these tools to be 
evaluated against each other, and for new tools that are more user-friendly to be 
developed. An accurate mutational signature relies heavily on the accuracy of the 
variant callers; consequently, the robustness of these mutational signatures needs to 
be evaluated further in a hypothesis-driven fashion.  
There are several limitations that need to be addressed in order to derive a full 
spectrum of mutational signatures. These limitations include the sample size, since at 
least 200 whole genome-sequencing samples were required to determine 20 
mutational signatures [81]. The second limitation is sequencing coverage, as exome 
sequencing covers approximately 1% of the human genome so fewer mutations are 
identified and effectively a large number of samples are required to determine the 
majority of mutational processes [88]. In order to address this particular issue 
deconstructSigs was developed [88]. This tool reconstructs the mutational profile 
within a single tumour sample rather than relying on a set of tumour samples. A 
multiple linear regression model is implemented using the fraction of mutations found 
in each of the 96-trinucleotide contexts in each tumour as input. The approach 
determines the weights that will best recreate the input data. Signatures are excluded 
if a single trinucleotide context comprises more than 20% of the signature, which is 
not present in the input data [88]. The reason for this exclusion is that some signatures 
are characterised largely by specific trinucleotide contexts and if these contexts are 
absent in the input data then the signature is unlikely to be active [88]. An initial 
mutational signature is chosen from the remaining signatures that best encompasses 
the mutational profile in a single tumour. A forward selection process then determines 
the optimal weight for each signature based on the contribution of the signature to the 
reconstructed profile.  The weight corresponding to that minimizes the sum squared 
error between the tumour sample and the reconstructed profile is subsequently 
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selected.  The weights are normalized to 0 and 1 and a reconstructed tumour profile is 
constructed based on the remaining weights [88].  
 
Clinical Utility of Mutation Signatures 
The clinical relevance of genome-scale patterns of DNA alterations has been 
investigated to gain an understanding of the mechanistic underpinnings of tumour 
aetiology, but also in particular to raise the possibility that genome profiling might be 
a useful clinical/diagnostic tool to aid patient management.   
In addition to the work described above, where substitution signatures of know 
aetiology can give insight into causes of some cancers (e.g. smoking, ultraviolet 
irradiation, DNA repair deficiency), a recent pioneering study examined the impact of 
ionizing radiation (IR) as a cancer-causing agent. The investigators identified patients 
who received radiotherapy in order to treat a cancer (of any type), but who then 
developed a second tumour within the field of the therapeutic IR. Whole genome 
sequencing of the second tumours revealed two unique patterns of mutation signature 
specifically associated with in vivo exposure to IR [89]. These mutation patterns 
involved a high rate of small (1-100 bp) deletions and balanced inversions, distributed 
throughout the genome, irrespective of the type of tumour analysed. This study gives 
in vivo insight into the precise role of IR in causing mutations to normal cells in the 
field of IR, which initiated the malignant process. 
Patterns of DNA alterations (loss of heterozygosity and copy number alterations) and 
DNA mutational signatures are also being developed as diagnostic tools to help 
stratify patients into certain treatment actionable groups. One area of great interest is 
in identifying tumours with homologous recombination (HR) deficiency. Between 1-
5% of breast cancers are attributable to germline mutations in BRCA1 and BRCA2, 
and as described above these tumours exhibit considerable genome instability 
indicative of HR deficiency. Importantly, BRCA1/2 deficient tumours also exhibit 
enhanced sensitivity to some DNA damaging chemotherapies, particularly platinum-
based compounds, or to targeted therapy using inhibitors to poly(ADP-ribose) 
polymerase (PARP) [90]. HR-deficient tumour cells exhibit considerable sensitivity 
to PARP inhibitors because PARP is involved in an alternative repair pathway called 
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base excision repair (BER). Hence, with BER inactivated, single strand breaks are not 
effectively repaired and they accumulate as double strand breaks during DNA 
replication, leading to replication fork collapse, enhanced genome instability and cell 
death. Genome-scale patterns could therefore be a biomarker of HR deficiency and 
hence sensitivity to PARP inhibitors or certain chemotherapies. Great interest has 
therefore been applied to develop ‘biomarkers’ of HR deficiency based on the pattern 
of somatic alterations identified in the tumour genome. These genome-based ‘tools’ 
utilise either aCGH or SNP array based genome data [64-71] or more recently whole 
genome sequencing data [91]. 
Several genome stability scores have been developed that use combinations of DNA 
copy number and/or allelic imbalance information to infer HR deficiency. For 
example, telomeric allelic imbalance (AI) is a subchromosomal region of AI that 
extends to the telomeric end of a chromosome. The number of telomeric AIs was 
associated with sensitivity to platinum-based therapy in triple negative breast cancer 
[71]. In another study, the total number of breakpoints within a tumour genome had 
no association with BRCA status, however the number of large-scale transitions 
(LST), defined as chromosomal breaks between adjacent regions of at least 10 Mb 
correlated with BRCA1 inactivation [69]. Loss of heterozygosity (LOH) was also 
strongly associated with BRCA deficiency [68]. These three genome-based scores 
(telomeric AI, LST and LOH) have been assessed as a combined homologous 
recombination deficiency (HRD) score (HRD Index) in various cohorts of breast 
cancer samples. The assay, developed using next generation sequencing, was 
collectively a more sensitive predictor of BRCA deficiency than individual parameters 
[92] and identified patients with increased benefit to neoadjuvant platinum based 
therapy [66, 93]. Similar findings have been reported reflecting the burden of allelic 
imbalanced copy number alterations and response to platinum-based chemotherapy 
[70]. 
A recent study applied whole genome sequencing data of breast cancers to develop a 
probabilistic predictor of HR deficiency [91]. Logistic lasso regression modelling was 
used to incorporate six genomic parameters, including substitution and rearrangement 
signatures and the HRD Index (described above) into a predictor, termed HRDetect. 
The predictor identified 22% of all breast tumours as being HR deficient, including 
tumours with germline or somatic biallelic inactivation of BRCA1/2, but also tumours 
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in which the cause of the HR deficiency was unclear. In a small pilot, the HRDetect 
score correlated with pathological response to neoadjuvant anthracycline 
chemotherapy[91]. This collective data indicates the potential for complex genome-
scale mutation data to be distilled into a simple diagnostic score that could be used 
clinically to identify patients who may gain benefit from certain chemotherapies or 
PARPi. 
Intratumour heterogeneity is a consequence of the acquisition of DNA mutations that 
drive the evolution of tumour cell clones with enhanced ‘fitness’. It is important to 
consider that the selective pressures of therapy may promote the accumulation of 
favourable mutations that lead to the development of treatment-resistant clones. The 
APOBEC substitution signature [43, 94] is a marker of APOBEC mutagenesis and 
has been linked to ensuing tumour evolution during progression and as a mechanism 
of resistance to treatment [95]. In breast cancer, a study has revealed that APOBEC3B 
could be a potential biomarker of tamoxifen resistance in ER+ disease [96]. The 
levels of ABOPEC3B in primary ER+ tumours inversely correlated with clinical 
benefit from tamoxifen treated metastatic disease. This finding was also validated in 
vitro using functional manipulation of APOBEC3B levels to either enhance tamoxifen 
response when APOBEC3B was depleted or to enhance resistance when APOBEC3B 
was overexpressed [96].  
 
Pioneering work using whole genome sequencing data has also identified a novel 
phenomenon known as kaetaegis [97], which is defined as clusters of mutations or 
hypermutation in concentrated genomic regions. Recent work has linked a 628 
kaetaegis gene expression signature to higher grade breast tumours that are HER2 
positive and have prolonged survival [98]. This study derived a signature based on a 
differential gene expression analysis between kaetaegis breast tumours and 106 
normal breast samples. The expression of genes proximal and distal to kataegis loci 
was reported. From these studies, it is clear that integration of the findings from 
whole genome sequencing data and transcriptomic data will reveal key signatures that 
explain breast cancer prognosis and disease aetiology.  
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Certainly, the area of cancer genomics has advanced significantly in recent years. 
Some of the findings highlighted here suggest that the unique insights being derived 
from different types of mutational profiling are revealing important insights into 
tumour biology, but also that they could make major contributions in the clinical 
management of patients, for example in the context of novel biomarkers that might 
predict therapeutic response. 
 
Conclusions 
There are increasing numbers of molecular signatures that are already commercially 
available, or are in pre-clinical development or show promise from the research 
setting. These advances illustrate the power of molecular approaches to stratify cancer 
into biologically and clinically meaningful subgroups beyond what is possible with 
standard clinical and pathological means of classification. Bioinformatics has also 
played a crucial role in the development and testing of these signatures, yielding 
numerous computational methods and tools for the use in the research/discovery 
setting. Hypothesis-driven research is imperative to validate and compare the 
performance of these gene signatures and bioinformatics tools across independent 
studies to ensure the findings are robust and reproducible. We have focused on breast 
cancer and genomic DNA and mRNA-based signatures, yet it is clear that these 
approaches reach across cancer types and advances in the signature profiling in the 
areas of epigenetics, miRNA, proteomics, and immune cell infiltrates will no doubt 
also play important clinical roles in the near future.  
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Table 1: Commercial mRNA-based gene signatures.  The associated assay details, 
platforms used to perform the diagnostic assay and the most appropriate patient 
populations are listed for each test.  
 
Test Assay Platform Patient population Ref 
OncotypeDx®  
(Genomic Health) 
21 genes  
FDA approved 
RT-PCR 
 
Stage I or II ER+, LN- 
and postmenopausal, LN+ 
[39] 
MammaPrint®  
(Agendia) 
70 genes  
FDA approved 
Microarray 
 
Stage I and II, ER+ or 
ER-, HER2+ or HER2-, 
LN- 
[38] 
MapQuantDx™ (GGI) 
(Ipsogen/QIAGEN) 
97 genes Microarray 
 
ER+, intermediate grade [36] 
ProSigna® (nanoString) 58 genes 
(PAM50) + 
clinical variables 
nanoString 
 
Stage I and II ER+, LN- [21] 
EndoPredict  
(Sividon/Myriad Genetics) 
12 genes + tumor 
size and nodal 
status 
RT-PCR 
 
ER+, HER2-, LN 0-3 [40] 
ER: oestrogen receptor; FDA: US Food and Drug Administration; LN: lymph nodes; RT-
PCR: Reverse Transcription- Polymerase Chain Reaction; -: negative; +: positive.  
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Table 2: Bioinformatics tools available for mRNA and DNA analyses.  The 
capability, as well as the associated strengths and limitations of each tool are 
described.   
Bioinformatics 
tools (URL) 
Aims Strengths Limitations References 
mRNA profiling         
Genefu 
 
http://bioconductor.o
rg/packages/release/
bioc/html/genefu.ht
ml 
Provides a compendia of 
bioinformatics tools and 
gene signatures for 
breast cancer subtyping 
and prognostication 
•Allows the quick manipulation of gene 
expression datasets, and has tools which 
facilitate gene selection and probe-gene 
mapping across platforms 
•Allows the comparison of multiple signatures 
(existing and novel) 
•Lack of documentation and 
simple tutorials for first-
time users 
[41] 
SigCheck 
 
 
http://bioconductor.o
rg/packages/release/
bioc/html/SigCheck.
html 
Provide methods for the 
assessment of a gene 
signature’s prognostic 
performance 
• Allows comparison of signatures 
performance against, random and known   
gene signatures 
  
 •Also allows the assessment of the signature’s 
performance on  permuted data and or 
metadata; useful to ascertain whether the 
signature has detected a real signal in the 
original data 
•Currently, the package only 
supports the division of 
samples into 2 to 3  distinct 
survival groups, based on 
the use of a threshold value 
or percentiles, respectively 
[35] 
DNA signatures       
 
SomaticSignatures 
 
https://bioconductor.
org/packages/release
/bioc/html/SomaticSi
gnatures.html 
Provide methods for the 
modelling, identification 
and visualisation of 
mutation signatures 
•Integrates well with Bioconductor tools and 
data structures for processing and annotating 
genomic variants 
•Supports multiple statistical approaches and 
other user-defined approaches 
•Relies on an unconstrained 
model, therefore limits the 
domain of signatures 
considered, as incorporating 
more distal bases result in a 
significant increase in the 
number of parameters, 
rendering the mutation 
signature unstable  
[83] 
Pmsignature 
 
https://github.com/fri
end1ws/pmsignature 
Provide methods for the 
modelling, identification 
and visualisation of 
mutation signatures 
•Provides intuitive visualisation of mutation 
signatures 
•Uses a probabilistic approach that reduces the 
number of parameters associated with each 
signature, thus allows the incorporation of 
additional sequence context (e.g., allows for 
incorporation of two bases 3’ and 5’of the 
substitution) 
Assumes independence 
between the mutation 
features (e.g., type of 
substitution is a feature, and 
flanking bases are each, 
individually, another 
feature) 
[87] 
deconstructSigs 
https://cran.r-
project.org/web/pack
ages/deconstructSigs
/ 
 Provides methods for 
the modelling, 
identification and 
visualisation of 
mutational signatures  
• Provides intuitive visualisation of mutation 
signatures 
• Determines mutation signatures in a single 
sample. 
 Assumes any coefficient in 
the multiple linear 
regression model must be 
greater than zero as negative 
contributions make no 
biological sense. 
[88] 
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Figure Legends 
Figure 1:  Conceptual overview of tumour grading and staging. 
A) Grading is a measure of tumour cell differentiation, relative to normal cells. 
Representative histological images of tumours of grade 1, 2 and 3 (see text) are 
shown, as stained with haemotoxylin and eosin. B) A pictorial representation of the 
tumour staging system. The different components of the TNM staging system are 
highlighted: T represents tumour size and extent of local invasion; N is a measure of 
tumour spread to regional lymph nodes (N); and M is a clinical assessment to record 
the extent of cancer metastasis to distant sites, such as the lung, liver, brain and bone.  
 
Figure 2: General overview of the signature development process. Each stage of 
this process is conducted within framework of human ethics approval, and should be 
subjected to quality control to ensure there is consistency and reproducibility.  
 
Figure 3: Conceptual overview of different subtype classification algorithms. 
This schematic illustrates an overview for the development of a Single Sample 
Predictor (SSP) or a Subtype Classification Model (SCM). The SSP does not 
necessarily involve a model and is calculated for each tumour sample, using a 
centroid computed from an intrinsic gene list.  Each calculated centroid is compared 
with predefined subtypes from a training set and the nearest centroid is used in the 
classification of a new tumour. SCMs involve gene modules rather than an intrinsic 
gene list and each new sample has a module score from the gene modules. The 
training cohort is classified into three distinct subtypes (ER-/HER2-, HER2+, 
ER+/HER2+) by fitting a 3 component Gaussian mixture model rather than using 
centroid based classification. Each new sample and module score is classified based 
on the maximum posterior probability using the model.  
 
Figure 4:  Conceptual overview of DNA mutational signatures.  The tumour 
genome is subjected to whole genome sequencing to identify somatic nucleotide 
alterations and structural variants. Substitution mutation signatures (left panel) are 
derived by calculating the frequency of all single base-pair mutations, in the context 
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of each mutation according to its neighbouring 3’ and 5’ nucleotides. A 96-
trinucleotide matrix, which consists of 96 substitutions by M samples is established 
and used in non-matrix factorization (NMF; or BayesNMF) to calculate the 
mutational signatures. The number of signatures (k) must be provided a priori in the 
NMF methodology and this can be calculated using the cophenetic correlation 
coefficient. Matrix A is split up into matrix W (96 x k matrix) and H (k x M matrix), 
where M is the number of samples.  
Rearrangement Signatures (right panel) are used to catalogue genomic rearrangements 
in cancer genomes. A piecewise constant fitting method is applied to discriminate 
between rearrangements that occurred as focal catastrophic events or focal driver 
amplicons (“clustered”) from genome-wide rearrangement mutagenesis (“non 
clustered”). The rearrangements are sub-classified based on type and size of the 
structural variation. This classification produces a 32-structural variant matrix which 
is decomposed using NMF.   
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Highlights 
 An overview of the commercially available prognostic signatures in breast cancer 
 Conceptual overview of the molecular signature development process in breast 
cancer  
 Aimed at biologists and computational biologists with an interest in gene 
signatures. 
 
 
